Skip to main content

Table 3 Univariate and multivariate analysis

From: Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Univariate analysis
OS HR Lower 95 % CI Upper 95 % CI p.value
 Gender (male or female) 0.76 0.34 1.67 0.5
 Age (<65 or 2^ 65) 0.98 0.94 1.03 0.5
 Performance status (0 or 1) 1.78 0.42 7.5 0.43
 Resection of primary tumor (yes or no) 0.7 0.2 1.6 0.43
 Ascitis (yes or no) 1.7 0.7 4.1 0.22
 Liver metastasis (yes or no) 1.2 0.59 2.6 0.55
 Lung metastasis (yes or no) 0.77 0.34 1.7 0.51
 Lymph metastasis (yes or no) 1.9 0.86 4.2 0.1
 Multiple metastasis (yes or no) 2.5 1.1 5.9 0.03
 Peritoneal metastasis (yes or no) 2.5 1.2 5.2 0.01
 Anti p53 antibody (positive or negative) 0.8 0.3 1.7 0.61
 IHC of p53 protein (positive or negative) 0.58 0.21 1.6 0.3
 KRAS (wild or mutant) 1.29 0.54 2.75 0.63
PFS
 Gender (male or female) 1.6 0.9 3.03 0.1
 Age (<65 or^65) 0.99 0.96 1.02 0.53
 Performance status (0 or 1) 1.8 0.23 2.47 0.64
 Resection of primary tumor (yes or no) 1.5 0.72 3.1 0.99
 Ascitis (yes or no) 0.6 0.28 1.43 0.29
 Liver metastasis (yes or no) 0.54 0.28 1 0.07
 Lung metastasis (yes or no) 2.8 1.59 5.2 4E-04
 Lymph metastasis (yes or no) 0.47 0.26 0.85 0.01
 Multiple metastasis (yes or no) 0.9 0.51 1.6 0.72
 Peritoneal metastasis (yes or no) 0.73 0.37 1.45 0.27
 Anti p53 antibody (positive or negative) 0.9 0.49 1.6 0.73
 IHC of p53 protein (positive or negative) 1 0.51 1.9 0.99
 KRAS (wild or mutant) 0.98 0.49 1.9 0.94
Multivariate analysis
OS HR Lower 95 % CI Upper 95 % CI p.value
 Peritoneal metastasis (yes or no) 2.3 1.1 5.1 0.02
PFS
 Lung metastasis (yes or no) 2.46 1.34 4.51 0.003
 Lymph metastasis (yes or no) 0.5 0.28 0.97 0.04